BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1840 related articles for article (PubMed ID: 27343697)

  • 1. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
    Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
    Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural Particulates Inspired Specific-Targeted Codelivery of siRNA and Paclitaxel for Collaborative Antitumor Therapy.
    Wang R; Zhao Z; Han Y; Hu S; Opoku-Damoah Y; Zhou J; Yin L; Ding Y
    Mol Pharm; 2017 Sep; 14(9):2999-3012. PubMed ID: 28753317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysosome-Independent Intracellular Drug/Gene Codelivery by Lipoprotein-Derived Nanovector for Synergistic Apoptosis-Inducing Cancer-Targeted Therapy.
    Wang W; Chen K; Su Y; Zhang J; Li M; Zhou J
    Biomacromolecules; 2018 Feb; 19(2):438-448. PubMed ID: 29334216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
    Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
    Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Green design "bioinspired disassembly-reassembly strategy" applied for improved tumor-targeted anticancer drug delivery.
    Wang R; Gu X; Zhou J; Shen L; Yin L; Hua P; Ding Y
    J Control Release; 2016 Aug; 235():134-146. PubMed ID: 27238442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-encapsulation of paclitaxel and baicalein in nanoemulsions to overcome multidrug resistance via oxidative stress augmentation and P-glycoprotein inhibition.
    Meng L; Xia X; Yang Y; Ye J; Dong W; Ma P; Jin Y; Liu Y
    Int J Pharm; 2016 Nov; 513(1-2):8-16. PubMed ID: 27596118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled release and reversal of multidrug resistance by co-encapsulation of paclitaxel and verapamil in solid lipid nanoparticles.
    Baek JS; Cho CW
    Int J Pharm; 2015 Jan; 478(2):617-24. PubMed ID: 25510604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancer.
    Bai F; Wang C; Lu Q; Zhao M; Ban FQ; Yu DH; Guan YY; Luan X; Liu YR; Chen HZ; Fang C
    Biomaterials; 2013 Aug; 34(26):6163-74. PubMed ID: 23706689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multifunctional mesoporous silica nanoparticles mediated co-delivery of paclitaxel and tetrandrine for overcoming multidrug resistance.
    Jia L; Li Z; Shen J; Zheng D; Tian X; Guo H; Chang P
    Int J Pharm; 2015 Jul; 489(1-2):318-30. PubMed ID: 25956050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance.
    Yu DH; Liu YR; Luan X; Liu HJ; Gao YG; Wu H; Fang C; Chen HZ
    Bioconjug Chem; 2015 Aug; 26(8):1702-12. PubMed ID: 26076081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic evaluation of multifunctional paclitaxel-loaded polymeric mixed micelles as a potential anticancer remedy to overcome multidrug resistance.
    Zhang J; Zhao X; Chen Q; Yin X; Xin X; Li K; Qiao M; Hu H; Chen D; Zhao X
    Acta Biomater; 2017 Mar; 50():381-395. PubMed ID: 27956367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel.
    McConathy WJ; Nair MP; Paranjape S; Mooberry L; Lacko AG
    Anticancer Drugs; 2008 Feb; 19(2):183-8. PubMed ID: 18176115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-assembly of biotinylated poly(ethylene glycol)-poly(curcumin) for paclitaxel delivery.
    Hu L; Li M; Zhang Z; Shen Y; Guo S
    Int J Pharm; 2018 Dec; 553(1-2):510-521. PubMed ID: 30308274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion.
    Liu Y; Zhou C; Wei S; Yang T; Lan Y; Cao A; Yang J; Hou Y
    Colloids Surf B Biointerfaces; 2018 Oct; 170():330-340. PubMed ID: 29936386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel.
    Hu H; Lin Z; He B; Dai W; Wang X; Wang J; Zhang X; Zhang H; Zhang Q
    J Control Release; 2015 Dec; 220(Pt A):189-200. PubMed ID: 26474677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. pH-Sensitive Biocompatible Nanoparticles of Paclitaxel-Conjugated Poly(styrene-co-maleic acid) for Anticancer Drug Delivery in Solid Tumors of Syngeneic Mice.
    Dalela M; Shrivastav TG; Kharbanda S; Singh H
    ACS Appl Mater Interfaces; 2015 Dec; 7(48):26530-48. PubMed ID: 26528585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of redox-responsive theranostic nanoparticles for near-infrared fluorescence imaging-guided photodynamic/chemotherapy of tumor.
    Yang X; Shi X; Ji J; Zhai G
    Drug Deliv; 2018 Nov; 25(1):780-796. PubMed ID: 29542333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor targeting effects of a novel modified paclitaxel-loaded discoidal mimic high density lipoproteins.
    Wang J; Jia J; Liu J; He H; Zhang W; Li Z
    Drug Deliv; 2013 Nov; 20(8):356-63. PubMed ID: 24079327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioresponsive and fluorescent hyaluronic acid-iodixanol nanogels for targeted X-ray computed tomography imaging and chemotherapy of breast tumors.
    Zhu Y; Wang X; Chen J; Zhang J; Meng F; Deng C; Cheng R; Feijen J; Zhong Z
    J Control Release; 2016 Dec; 244(Pt B):229-239. PubMed ID: 27568289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Biomimetic Nanoparticles for Synergistic Combination Chemotherapy of Paclitaxel and Doxorubicin.
    Rui M; Xin Y; Li R; Ge Y; Feng C; Xu X
    Mol Pharm; 2017 Jan; 14(1):107-123. PubMed ID: 27982602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 92.